The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
Combines BMO's market-leading global metals and mining franchise with premier Australian distribution platform, strengthening BMO's position as the leading global metals...
The IEEPA (International Emergency Economic Powers Act) tariff program was introduced in February 2025 and expanded through April 2025. Following the U.S Supreme Court's ruling in February 2026...
FREMONT, Calif., HAMBURG, Germany and SHENZHEN, China, June 30, 2026 /PRNewswire/ -- Ohuhu, one of the leading global art supplies brands, is celebrating its 10th...
First-of-its-kind in agentic CPG procurement — Knowledge Graph, AI Agent Skills and Global Rollout TORONTO, BARCELONA and SYDNEY, June 30, 2026 /PRNewswire --...
